Skip to main content
SpringerLink
Log in

The Economic Aspects of Drug Delivery in Asthma

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The need for cost-effective asthma therapy is driven by the high prevalence of asthma as well as the high cost of both medical care and lost productivity through illness. Limited healthcare resources demand proven therapies that maintain sustained disease control. Optimal disease control is the essence of cost effectiveness, but this in turn is dependent on correct drug selection and appropriate drug delivery. Successful treatment depends on delivery of medication to the site of action in the airways. Although there is a substantial number of aerosol delivery systems available, there is considerable confusion as to the most suitable method in different clinical settings, and across different age groups. Optimal drug delivery can be achieved without adding substantially to the overall cost of therapy. Both drugs and delivery systems need to be individualised to the needs of the patients. The early introduction of oral corticosteroids for acute exacerbations has resulted in reduced hospitalisation and shortened illness, providing substantial cost savings. A reduction in the reliance on nebuliser therapy in both the acute and chronic setting will further optimise therapy and reduce costs. We have reviewed the current literature to determine the most cost-effective methods of drug delivery in asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Asthma Campaign. Report on the cost of asthma in Australia. Melbourne, Australia: National Asthma Society, 1992

    Google Scholar 

  2. Weiss KB, Gergon PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862–6

    Article  PubMed  CAS  Google Scholar 

  3. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: can it be reduced? Pharmacoeconomics 1993; 3: 205–19

    Article  PubMed  CAS  Google Scholar 

  4. Global Initiative for Asthma. Global strategy for asthma management and prevention. HHLBI/WHO workshop report, March 1993. The National Heart, Lung and Blood Institute. Publication number 95-369, Jan 1995

  5. Sullivan SD. Cost-effectiveness of drug interventions. Eur Respir Rev 1996; 35: 116–8

    Google Scholar 

  6. Ädelroth E, Thompson S. Advantages of high-dose inhaled budesonide. Lancet 1988; I: 476

    Article  Google Scholar 

  7. Gerdtham UG, Hertzman P, Boman G, et al. Impact of inhaled corticosteroids on asthma hospitalization in Sweden: a pooled regression analysis. Research Report of the Ekonomiska Forskningsinsitutet, Center for Health Economics, Stockholm School of Economics 1993

  8. Ross RN, Morris M, Sakowitz SR, et al. Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. Clin Ther 1988; 10(2): 188–203

    PubMed  CAS  Google Scholar 

  9. Perera BJ Efficacy and cost-effectiveness of inhaled steroids in asthma in a developing country. Arch Dis Child 1995; 72: 312–15

    Article  PubMed  CAS  Google Scholar 

  10. Connett GJ, Lenney W, McConchie SM. The cost-effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ 1993; 6: 127–134

    Google Scholar 

  11. Rutten-van Molken MPMH, Van Doorslaer EKA, Jansen MCC, et al. Cost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics 1993; 4(4): 257–70

    Article  PubMed  CAS  Google Scholar 

  12. Campbell LM, Simpson RJ, Turbitt ML, et al. A comparison of the cost-effectiveness of budesonide 400 µg/day and 800 µg/day in the management of mild-to-moderate asthma in general practice. Br J Med Econ 1993; 6: 67–74

    Google Scholar 

  13. Rutten-van-Mölken MP, Van-Doorslaer EK, Jansen MC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975–982

    PubMed  Google Scholar 

  14. Newhouse MT, Dolovitch MB. Control of asthma by aerosols. N Engl J Med 1986; 314: 870–3

    Article  Google Scholar 

  15. Keeley D. Large volume plastic spacers in asthma. BMJ 1992; 305: 598–9

    Article  PubMed  CAS  Google Scholar 

  16. Ross RN. The costs of managing asthma. J Resp Dis 1989; Suppl.: S15–20

    Google Scholar 

  17. Levison H. Spacers in childhood asthma — is there one for all occasions? Ann Allergy 1990; 64: 323–4

    PubMed  CAS  Google Scholar 

  18. Newhouse MT. Hospital-based asthma education: achieving the goals and evaluating the outcome. Chest 1994; 106 Suppl.: S237–41

    Article  Google Scholar 

  19. Newhouse MT, Dolovitch MB. Control of asthma by aerosols. N Engl J Med 1986; 314: 870–3

    Article  Google Scholar 

  20. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50: 105–10

    Article  PubMed  CAS  Google Scholar 

  21. Brunette MG, Lands L, Thibodeau L-P. Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. Pediatrics 1988; 81: 624–9

    PubMed  CAS  Google Scholar 

  22. Storr J, Barrell E, Barry W, et al. Effect of a single oral dose of prednisolone in acute childhood asthma. Lancet 1987; I: 879–81

    Article  Google Scholar 

  23. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996; 334: 1380–88

    Article  PubMed  CAS  Google Scholar 

  24. Tenholder MF, Bryson MJ, Whitlock WL. A model for conversion from small volume nebulizer to metered dose inhaler aerosol therapy. Chest 1992; 101: 634–7

    Article  PubMed  CAS  Google Scholar 

  25. Ruffin RE, Kenworthy MC, Newhouse MT. Response of asthmatic patients to fenoterol inhalation: a method of quantifying the airway bronchodilator dose. Clin Pharmacol Ther 1978; 23: 338–45

    PubMed  CAS  Google Scholar 

  26. Kendrik A, Smith EC. Domiciliary bronchodilator therapy: comparison of aeroflow, sidestream, misty neb, micromist and updraft II nebuliser chambers available in Australia [abstract no. 122]. Proceedings of Annual Scientific Meeting Thoracic Society of Australia and New Zealand, 1996

  27. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (Ventstream). Thorax 1994; 49: 762–70

    Article  PubMed  CAS  Google Scholar 

  28. Gibson PG, Wlodarczyk JH, Borgas T. Drug delivery in asthma: a comparison of spacers with a jet nebuliser. Aust N Z J Med 1995; 25: 324–29

    Article  PubMed  CAS  Google Scholar 

  29. Summer W, Elston R, Tharpe L, et al. Aerosol bronchodilator delivery methods: relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989; 149: 618–23

    Article  PubMed  CAS  Google Scholar 

  30. Bowton DL, Goldsmith WM, Haponik EF. Substitution of metered-dose inhalers for hand held nebulisers: success and cost savings in a large, acute care hospital. Chest 1992; 101: 305–8

    Article  PubMed  CAS  Google Scholar 

  31. Melchor R, Biddiscome MF, Mak VHF, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstructions. Thorax 1993; 48: 506–11

    Article  PubMed  CAS  Google Scholar 

  32. Frew AJ, MacFarlane JTM. Are medical staff any better at using inhalers than patients [abstract]? Thorax 1992; 37: 780

    Google Scholar 

  33. Nelson HS, Loffert DT. Comparison of the bronchodilator response to albuterol administered by the OptiHaler, the Aerochamber, or by metered dose inhaler alone. Ann Allergy 1994; 72: 337–40

    PubMed  CAS  Google Scholar 

  34. Barry PW, Robertson CF, O’Callaghan C. Optimum use of a spacer device. Arch Dis Child 1993; 69: 693–4

    Article  PubMed  CAS  Google Scholar 

  35. Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984; 129: 723–9

    PubMed  CAS  Google Scholar 

  36. Wildhaber J, Devadason S, Hayden M, et al. Electrostatic charge influences salbutamol delivery from plastic spacers [abstract no. 126]. Proceedings of Annual Scientific Meeting Thoracic Society of Australia and New Zealand, 1996

  37. Newman S, Miller A, Lennard Jones T, et al. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39: 935–41

    Article  PubMed  CAS  Google Scholar 

  38. Borgstrom L, Bondesson E, Morem F, et al. Lung deposition of budesonide inhaled via Turbuhaler: comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69–73

    Article  PubMed  CAS  Google Scholar 

  39. Lofdahl CG, Anderson L, Carlsson LG, et al. Lower nominal dose of inhaled salbutamol via Turbuhaler compared with pressurised metered dose inhaler, for the same bronchodilating effect [abstract]. Am J Respir Crit Care Med 1994; 149: A219

    Google Scholar 

  40. Agertoft I, Pederson S. Importance of the inhalation device on the effects of budesonide. Arch Dis Child 1993; 69: 130–3

    Article  PubMed  CAS  Google Scholar 

  41. King D, Earnshaw SM, Delany JC. Pressurised aerosol inhalers: the cost of misuse. Br J Clin Practice 1991; 45(1): 48–9

    CAS  Google Scholar 

  42. Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 µg/day) administered either as dry powder via a Diskhaler® or pressurised inhaler and compared with beclomethasone dipropionate (1000 µg/day) administered by pressurised inhaler. Resp Med 1993; 87: 609–20

    Article  CAS  Google Scholar 

  43. Brunette GM, Lands L, Thibodeau L-P. Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. Pediatrics 1988; 81: 624–9

    PubMed  CAS  Google Scholar 

  44. Storr J, Barrell E, Barry W, et al. Effect of a single oral dose of prednisolone in acute childhood asthma. Lancet 1987; I: 879–81

    Article  Google Scholar 

  45. Harrison BDW, Stokes TC, Hart GJ, et al. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet 1986; I: 181–4

    Article  Google Scholar 

  46. Karem E, Levison H, Schuh S, et al. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr 1993; 123: 313–7

    Article  Google Scholar 

  47. Pendergast J, Hopkins J, Timms B, et al. Comparative efficacy of terbutaline administered by Nebuhaler and by nebuliser in young children with acute asthma. Med J Aust 1989; 151: 406–8

    PubMed  CAS  Google Scholar 

  48. Parkin PC, Saunders NR, Diamond SA, et al. Randomised trial spacer v nebuliser for acute asthma. Arch Dis Child 1995; 72: 239–40

    Article  PubMed  CAS  Google Scholar 

  49. Tenholder MF, Bryson MJ, Whitlock WL. A model for conversion from small volume nebulizer to metered dose inhaler aerosol therapy. Chest 1992; 101: 634–37

    Article  PubMed  CAS  Google Scholar 

  50. Clark NM, Feldman CH, Evans D, et al. The impact of health education on frequency and cost of health care use by low income children with asthma. J Allergy Clin Immunol 1986; 78: 108–15

    Article  PubMed  CAS  Google Scholar 

  51. Windsor RA, Bailey WC, Richards JM, et al. Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma. Am J Public Health 1990; 80: 1519–21

    Article  PubMed  CAS  Google Scholar 

  52. Bolton MB, Tilley BC, Kuder J, et al. The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med 1991; 6: 401–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, New Children’s Hospital, Royal Alexandra Hospital for Children, PO Box 3515, Parramatta, New South Wales, 2124, Australia

    R. John Massie & Craig M. Mellis (Associate Professor)

Authors
  1. R. John Massie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig M. Mellis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig M. Mellis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Massie, R.J., Mellis, C.M. The Economic Aspects of Drug Delivery in Asthma. PharmacoEconomics 11, 398–407 (1997). https://doi.org/10.2165/00019053-199711050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00003

Keywords

Search

Navigation